ATNM Projected Dividend Yield
Actinium Pharmaceuticals Inc ( AMEX : ATNM )Actinium Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. Co. is engaged in developing targeted radiotherapies to improve survival for people who have failed existing oncology therapies. Co.'s advanced pipeline candidates include Iomab-B (pre-BLA & MAA (EU)) and Actimab-A. Iomab-B is an induction and conditioning agent prior to bone marrow transplant. Actimab-A is a therapeutic agent, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. Co. focuses on advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. 20 YEAR PERFORMANCE RESULTS |
ATNM Dividend History Detail ATNM Dividend News ATNM Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |